Compare IZM & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZM | MRKR |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 16.6M |
| IPO Year | 2023 | N/A |
| Metric | IZM | MRKR |
|---|---|---|
| Price | $1.05 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.17 |
| AVG Volume (30 Days) | 54.6K | ★ 345.5K |
| Earning Date | 10-24-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $187,048,691.00 | $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $0.87 | $0.81 |
| 52 Week High | $2.74 | $5.95 |
| Indicator | IZM | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 57.89 |
| Support Level | $0.89 | $1.25 |
| Resistance Level | $1.25 | $1.48 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 59.37 | 64.71 |
ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.